Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Clinical Roundup

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

In Brief

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes.

April 18, 2025

Vol.51 No.15

In Brief

Casirati, De Wolf, Persaud, Rehman awarded $260,000 research grants from DKMS

Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.

April 11, 2025

Vol.51 No.14

Clinical Roundup

NK cells complexed with bispecific antibody yield high response rates in lymphoma

A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.

April 11, 2025

Vol.51 No.14

Ribociclib added to endocrine therapy extends survival in postmenopausal metastatic breast cancer patients

YOU MAY BE INTERESTED IN

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Casirati, De Wolf, Persaud, Rehman awarded $260,000 research grants from DKMS

NK cells complexed with bispecific antibody yield high response rates in lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login